НОВАРТИС ВЭКСИНЕС ЭНД ДАЙЭГНОСТИКС ГМБХ УНД КО КГ (DE)
发明人:
БОРКОВСКИ Астрид (DE)
申请号：
RU2012116119/15
公开号：
RU2012116119A
申请日:
2012.04.20
申请国别(地区):
RU
年份:
2013
代理人:
摘要：
1. An immunization kit comprising a first immunogenic component and a second immunogenic, wherein: (a) the first immunogenic contains an aqueous composition of a conjugated capsular saccharide； and (b) the second immunogenic component contains a conjugated capsular saccharide serogroup C, where the second immunogenic component does not contain aluminum phosphate salt. The kit of claim 1, wherein the second immunogenic component does not contain an adjuvant. 3. The kit of claim 1, wherein the second immunogenic component does not contain an aluminum hydroxide adjuvant. The kit of claim 1, wherein the second immunogenic component comprises an aluminum phosphate adjuvant. The kit according to claim 1, where the second immunogenic component is an aqueous composition. The kit of claim 1, wherein the second immunogenic component is a lyophilized composition. The kit according to any one of claims 1 to 6, where the first and / or second component further comprises one or more of the group: diphtheria toxoid； tetanus toxoid； antigen (s)； hepatitis B virus surface antigen； and inactivated poliovirus antigen. 8. The kit according to claim 7, where (a) the first component contains each of: diphtheria toxoid； tetanus toxoid； antigen (s)； hepatitis B virus surface antigen； and inactivated poliovirus antigen； or (b) a second component contains each of: diphtheria toxoid； tetanus toxoid； antigen (s)； hepatitis B virus surface antigen； and inactivated poliovirus antigen； or (c) the kit contains a third immunogenic component, which contains each of: diphtheria toxoid； tetanus toxoid； antigen (s)； hepatitis B virus surface antigen； and inactivated poliovirus antigen. 9. The set of claim 8, where the first1. Набор для иммунизации, содержащий первый иммуногенный компонент и второй иммуногенный, где:(a) первый иммуногенный содержит водный состав конъюгированного капсульного сахарида； и(b) второй иммуногенный компонент содержит конъюгированный капсульный сахаридсерогруппы C, где второй и
